This page uses content from Wikipedia and is licensed under CC BY-SA.


Flualprazolam structure.svg
Legal status
Legal status
CAS Number
PubChem CID
Chemical and physical data
Molar mass326.76 g·mol−1
3D model (JSmol)

Flualprazolam is a benzodiazepine derivative which was first synthesised in 1976,[1] but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified in Sweden in 2018.[2] It can be described as the 2'-fluoro derivative of alprazolam, or the fluoro instead of chloro analogue of triazolam, and has similar sedative and anxiolytic effects.[3][4][5][6]

See also


  1. ^ Hester JB, et al. 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Patent US 3987052
  2. ^ Svenska Narkotika Polisföreningens Tidskrift, June 1 2018
  3. ^ Waters L, Manchester KR, Maskell PD, Haegeman C, Haider S. The use of a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding of newly emerging benzodiazepines. Science and Justice. 2018 Jan 8. doi:10.1016/j.scijus.2017.12.004
  4. ^ Zawilska JB, Wojcieszak J. An expanding world of New Psychoactive Substances – Designer benzodiazepines. NeuroToxicology 2019 July; 73: 8-16. doi:10.1016/j.neuro.2019.02.015
  5. ^ Moosmann B., Auwärter V. (2018) Designer Benzodiazepines: Another Class of New Psychoactive Substances. In: Maurer H., Brandt S. (eds) New Psychoactive Substances. Handbook of Experimental Pharmacology, vol 252. doi:10.1007/164_2018_154
  6. ^ Chetraru E, Ameline A, Gheddar L, Raul JS, Kintz P. Les designer benzodiazepines: qu’en sait-on aujourd’hui?. Toxicologie Analytique et Clinique. 2018 Feb 1;30(1):5-18. doi:10.1016/j.toxac.2017.12.001